1 Min Read
* Transition therapeutics announces dosing of first patient in phase 2 study of drug candidate tt701 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.